Vaxcyte Inc [NASDAQ: PCVX] loss -1.67% on the last trading session, reaching $35.24 price per share at the time.
If compared to the average trading volume of 2.01M shares, PCVX reached a trading volume of 3845145 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Vaxcyte Inc [PCVX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PCVX shares is $129.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PCVX stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Vaxcyte Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on April 22, 2025. While these analysts kept the previous recommendation, Goldman raised their target price to Buy. The new note on the price target was released on December 20, 2024, representing the official price target for Vaxcyte Inc stock. Previously, the target price had yet another raise to $69, while Mizuho analysts kept a Buy rating on PCVX stock.
The Average True Range (ATR) for Vaxcyte Inc is set at 3.45 The Price to Book ratio for the last quarter was 1.33, with the Price to Cash per share for the same quarter was set at 13.54.
Trading performance analysis for PCVX stock
Vaxcyte Inc [PCVX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.12. With this latest performance, PCVX shares gained by 9.34% in over the last four-week period, additionally sinking by -68.76% over the last 6 months – not to mention a drop of -42.26% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PCVX stock in for the last two-week period is set at 39.50, with the RSI for the last a single of trading hit 48.32, and the three-weeks RSI is set at 35.87 for Vaxcyte Inc [PCVX]. The present Moving Average for the last 50 days of trading for this stock 54.84, while it was recorded at 34.33 for the last single week of trading, and 84.14 for the last 200 days.
Vaxcyte Inc [PCVX]: A deeper dive into fundamental analysis
Vaxcyte Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.75 and a Current Ratio set at 12.75.
Vaxcyte Inc [PCVX]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PCVX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Vaxcyte Inc go to -6.42%.
An analysis of Institutional ownership at Vaxcyte Inc [PCVX]
There are presently around $111.69%, or 112.25%% of PCVX stock, in the hands of institutional investors. The top three institutional holders of PCVX stocks are: FMR LLC with ownership of 16.17 million shares, which is approximately 13.788%. BLACKROCK INC., holding 9.94 million shares of the stock with an approximate value of $$750.56 million in PCVX stocks shares; and BLACKROCK INC., currently with $$739.77 million in PCVX stock with ownership which is approximately 8.3552%.
